日本大鹏药品工业株式会社(Taiho Pharmaceutical Co., Ltd.)是一家成立于1963年集医药、保健品、健康食品等研发、生产和销售为一体的综合性制药企业，年销售额超过10亿美元，总资产超过26亿美元，产品涉及肿瘤、泌尿、免疫系统，并在抗肿瘤领域居世界领先位置。公司总部位于日本东京，在日本拥有3个研究所、1个研发中心和4家药品生产基地，并在美国、韩国、新加坡、中国设立分支机构，员工超过2500人。
为适应中国医药品市场规模的迅速扩大以及日本新版抗癌药临床研究指导原则的全面实施，本公司于2006年8月设立北京代表处，负责按照ICH-GCP以及国家相关法规严格进行各种临床研究（包括国际多中心临床试验），从而向国内外广大患者提供有更加有效的治疗药物。
随着中国经济的迅速发展和国内医药行业与国际水平接轨，我们相信在不久的将来本公司的中国事业将会得到进一步发展。我们衷心期待各位有志之士能够加入我们的队伍，为中国事业的成功而共同努力。
Taiho Pharmaceutical Co., Ltd, established in 1963, is an integrated pharmaceutical company which commits itself to R&D, manufacturing and distribution of pharmaceuticals, health care products, and healthy foods. Taiho stays ahead of the world in anti-cancer drugs, and has products in the field of urology and allergy/immunology. With headquarter located in Tokyo, three research centers, one R&D center and 4 manufacturers across Japan, Taiho achieves total assets over 2.6 billion US dollars and net sale over of 1 billon dollars per year. Nowadays, Taiho has over 2500 employees and 4 branches in U.S, Korea, Singapore and China.
Because of the great expansion of pharmaceutical market in China and the new clinical research guideline for anticancer drugs in Japan, Taiho established its Beijing representative office in Aug. 2006. Our Beijing Office is responsible for conducting clinical trials (including global multicenter studies) in accordance with ICH-GCP and related regulations, so as to find more effective drugs for patients all over the world.
Due to the rapid growth of economy and the international standardization of R&D activities in China, we believe our China business will rapidly develop in the near future. We are expecting ambitious candidates to join us for the success of Taiho in China.
More information, please refer to our homepage: http://www.taiho.co.jp/
